Progress in SARS-CoV-2, Diagnostic and Clinical Treatment of COVID-19

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Jul 18

PMID 39021908

Authors

Yang Li

Si-Ming Lu

Jia-Long Wang

Hang-Ping Yao

Li-Guo Liang

Affiliations

Soon will be listed here.

Abstract

Background: Corona Virus Disease 2019(COVID-19)is a global pandemic novel coronavirus infection disease caused by Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Although rapid, large-scale testing plays an important role in patient management and slowing the spread of the disease. However, there has been no good and widely used drug treatment for infection and transmission of SARS-CoV-2.

Key Findings: Therefore, this review updates the body of knowledge on viral structure, infection routes, detection methods, and clinical treatment, with the aim of responding to the large-section caused by SARS-CoV-2. This paper focuses on the structure of SARS-CoV-2 viral protease, RNA polymerase, serine protease and main proteinase-like protease as well as targeted antiviral drugs.

Conclusion: or clinical trials have been carried out to provide deeper thinking for the pathogenesis, clinical diagnosis, vaccine development and treatment of SARS-CoV-2.

Citing Articles

Simultaneous determination of nirmatrelvir, ritonavir, and beta-D-N4-hydroxycytidine in human plasma and epithelial lining fluid using LC-MS/MS and its clinical application to compare rates of achieving effective concentrations.

Zhang W, Xia L, Yuan Z, Liu M, Jiao Y, Wang Z Heliyon. 2025; 11(2):e41737.

PMID: 39882486 PMC: 11774765. DOI: 10.1016/j.heliyon.2025.e41737.

Pyrrolidines as Main Protease Inhibitors for Treating Viral Infections, in Particular, Coronavirus Infections.

Sabnis R ACS Med Chem Lett. 2024; 15(12):2097-2098.

PMID: 39691512 PMC: 11647677. DOI: 10.1021/acsmedchemlett.4c00553.

Enhancing Transfection Efficacy in Glioma Cells: A Comparison of Microfluidic Manual Polypropylenimine Dendriplex Formation.

Ali-Jerman H, Al-Quraishi Z, Muglikar A, Perrie Y, Tate R, Mullin M Int J Nanomedicine. 2024; 19:12189-12203.

PMID: 39588254 PMC: 11588423. DOI: 10.2147/IJN.S490936.

Novel Papain-Like Protease Inhibitors for Treating Viral Infections, in Particular Coronavirus Infections.

Sabnis R ACS Med Chem Lett. 2024; 15(11):1802-1803.

PMID: 39563803 PMC: 11571084. DOI: 10.1021/acsmedchemlett.4c00474.

Novel Papain-Like Protease Inhibitors for Treating Viral Infections, in particular, Coronavirus Infections.

Sabnis R ACS Med Chem Lett. 2024; 15(8):1186-1187.

PMID: 39140061 PMC: 11318001. DOI: 10.1021/acsmedchemlett.4c00331.

References

Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S . Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020; 383(24):2320-2332. PMC: 7494251. DOI: 10.1056/NEJMoa2026920. View

Elfiky A . Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J Med Virol. 2016; 88(12):2044-2051. DOI: 10.1002/jmv.24678. View

Te Velthuis A, Arnold J, Cameron C, van den Worm S, Snijder E . The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent. Nucleic Acids Res. 2009; 38(1):203-14. PMC: 2800238. DOI: 10.1093/nar/gkp904. View

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y . Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun. 2020; 11(1):4417. PMC: 7474075. DOI: 10.1038/s41467-020-18233-x. View

Amani B, Amani B . Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. J Med Virol. 2022; 95(2):e28441. PMC: 9880713. DOI: 10.1002/jmv.28441. View

Hilgenfeld R . From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014; 281(18):4085-96. PMC: 7163996. DOI: 10.1111/febs.12936. View

10.

Zhang H, Rostami M, Leopold P, Mezey J, OBeirne S, Strulovici-Barel Y . Expression of the SARS-CoV-2 Receptor in the Human Airway Epithelium. Am J Respir Crit Care Med. 2020; 202(2):219-229. PMC: 7365377. DOI: 10.1164/rccm.202003-0541OC. View

11.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

12.

Channappanavar R, Fehr A, Zheng J, Wohlford-Lenane C, Abrahante J, Mack M . IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019; 129(9):3625-3639. PMC: 6715373. DOI: 10.1172/JCI126363. View

13.

Elfiky A, Elshemey W . IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study. Med Chem Res. 2020; 25(5):1005-1008. PMC: 7080126. DOI: 10.1007/s00044-016-1533-y. View

14.

Fomsgaard A, Rosenstierne M . An alternative workflow for molecular detection of SARS-CoV-2 - escape from the NA extraction kit-shortage, Copenhagen, Denmark, March 2020. Euro Surveill. 2020; 25(14). PMC: 7160440. DOI: 10.2807/1560-7917.ES.2020.25.14.2000398. View

15.

Moghadasi S, Heilmann E, Khalil A, Nnabuife C, Kearns F, Ye C . Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Sci Adv. 2023; 9(13):eade8778. PMC: 10058310. DOI: 10.1126/sciadv.ade8778. View

16.

Anderson A, Caubel P, Rusnak J . Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19. N Engl J Med. 2022; 387(11):1047-1049. PMC: 9513855. DOI: 10.1056/NEJMc2205944. View

17.

Kuba K, Imai Y, Ohto-Nakanishi T, Penninger J . Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther. 2010; 128(1):119-28. PMC: 7112678. DOI: 10.1016/j.pharmthera.2010.06.003. View

18.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

19.

Osipiuk J, Azizi S, Dvorkin S, Endres M, Jedrzejczak R, Jones K . Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat Commun. 2021; 12(1):743. PMC: 7854729. DOI: 10.1038/s41467-021-21060-3. View

20.

Hung I, Lung K, Tso E, Liu R, Chung T, Chu M . Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238):1695-1704. PMC: 7211500. DOI: 10.1016/S0140-6736(20)31042-4. View